Extended Input Deadline for USP´s new Chapter on Quality Considerations for Cannabis
Register now for ECA's GMP Newsletter
Following the previously announced elaboration of a new USP chapter <1568> Quality Considerations for Cannabis and Cannabis-derived Products for Clinical Research the input deadline has been extended to 31 July 2022.
USP is requesting early input from stakeholders on the proposed new General Chapter <1568> which is then expected to be published for comment in Pharmacopeial Forum.
More Information is available at the USP Compendial Notices Website.
Related GMP News
30.01.2025FDA seeks Feedback on Opiate Alkaloid Content of Poppy Seeds
30.01.2025Ensuring Microbiological Quality of Herbal Products
30.01.2025Research with Recreational Cannabis in Germany - Which Agency is Responsible?
15.10.2024Real-World Data Requirements for Herbal Medicinal Products
01.08.2024USP Cannabis Monograph
01.08.2024FDA issues Warning Letters for Selling Products containing Delta-8 THC